MEDICORTEX-FINLAND-OY
9.8.2021 08:20:07 CEST | Business Wire | Press release
Medicortex Finland Oy (www.medicortex.fi ) and Dividend Sweden AB (www.dividendsweden.se ) announced signing an agreement whereby Dividend will invest in Medicortex as a part of a pre-IPO round Medicortex is currently conducting. The funding provided to Medicortex will support the activities related to a dual listing of Medicortex on Nasdaq First North in both Helsinki and Stockholm.
“The investment made by Dividend is a clear proof of trust in Medicortex’s technology and future. Dividend brings a large pool of investors that will support the IPO” says Dr. Adrian Harel, CEO of Medicortex Finland Oy.
Medicortex is working towards the validation of biomarker-based diagnostics for mild Traumatic Brain Injury (TBI). Medicortex is developing a quick and reliable hand-held kit (ProbTBITM ) that can be easily used by first responders, healthcare professionals and army paramedics.
Göteborg Corporate Finance (GCF) acted as financial advisor to Medicortex during the pre-IPO and has also been appointed as financial advisor for the upcoming IPO and dual listing at Nasdaq First North Helsinki and Stockholm.
About Medicortex
Medicortex Finland Oy (www.medicortex.fi ) is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is to develop biomarker diagnostics to evaluate TBI. The next goal of the company will be to develop an innovative drug to halt the progression of the initial brain injury.
Forward-Looking Statements
This press release contains statements that are "forward-looking statements" that are based upon management's current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated herein.
Keywords : pre-IPO, Medicortex, Traumatic Brain Injury, Diagnostics, Dividend
View source version on businesswire.com: https://www.businesswire.com/news/home/20210808005032/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MASARAT Mobility Park Welcomes FPI Gulf as Anchor Tenant for Advanced Automotive Parts Manufacturing10.2.2026 08:48:00 CET | Press release
MASARAT Mobility Park has entered into a development lease agreement with FPI Gulf to establish an automotive parts manufacturing facility, marking a key milestone in the Park’s development. This agreement strengthens MASARAT Mobility Park’s position as the premier destination for localizing the automotive and mobility value chain in Saudi Arabia. At the PIF Private Sector Forum 2026, MASARAT Mobility Park announced the signing of a development lease agreement with Fortune Parts Industry Gulf (FPI Gulf), a Joint venture between Thailand based FPI Group and local partner Fuel Autoparts Company. This milestone represents a significant step in the Park’s development and supports the localization of automotive manufacturing in the Kingdom, in line with Vision 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211304060/en/ From left to right: Noppawit Tanadumrongsak, Managing Director of FPI India; Abdulrahman Binmahfooz, M
MASARAT Mobility Park Announced Agreements with TASARU Supplier Hub to Advance Automotive Manufacturing Localization10.2.2026 08:11:00 CET | Press release
MASARAT Mobility Park signed development-lease agreements with TASARU Supplier Hub to accelerate industrial localization and strengthen Saudi Arabia’s automotive supply chain. These agreements enable TASARU Supplier Hub to establish operations at MASARAT Mobility Park to host leading automotive suppliers, reinforcing the Park’s role as a premier destination for automotive and mobility industries. MASARAT Mobility Park, Saudi Arabia’s premier destination for automotive and mobility industries, has entered into development lease agreements with TASARU Supplier Hub, a strategic initiative by TASARU Mobility Investments (a PIF company) This partnership underpins long-term industrial localization, reinforces the national automotive supply chain, and significantly enhances the Park’s value proposition for Original Equipment Manufacturers (OEMs) and suppliers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210736469/en/ From lef
Dealroom and NATO Innovation Fund: European Defence, Security & Resilience Startups Smash Record with $8.7B Raised in 202510.2.2026 07:05:00 CET | Press release
The 55% year on year surge was fuelled by late-stage mega rounds, indicating a maturing ecosystem to address NATO’s capability needs.Munich retained its position as Europe's #1 DSR hub, with the UK attracting the most VC funding and Central and Eastern Europe showing the largest growth.AI dominated the sector, underpinning 44% of all DSR funding. An exclusive new report by Dealroom and the NATO Innovation Fund shows that European DSR (Defence, Security and Resilience) startups secured a record $8.7 billion in venture capital in 2025. The surge was fuelled by late-stage mega-rounds to support breakthrough technologies that help address critical capabilities for NATO nations – from freedom of operations & mobility, to awareness and decision making, and the security of critical technologies. Record funding surge powers DSR Startups to meet NATO nations’ most urgent security needs Funding for DSR startups increased by 55% year on year and is nearly four times higher than five years ago. It
4Moving Biotech Announces the Closing of a €12 Million Financing to Advance a First-in-Class DMOAD in Knee Osteoarthritis10.2.2026 06:52:00 CET | Press release
- Funding secured, extending the financial runway to reach a proof-of-concept inflection point - Company’s attractiveness reinforced through the onboarding of new investors 4Moving Biotech (4MB), a clinical-stage biotechnology company and a spin-off of 4P-Pharma, developing a first-in-class disease-modifying osteoarthritis drug (DMOAD) for knee osteoarthritis, today announced the closing of a €12 million financing, completed through a structured and coordinated funding process. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209500141/en/ Francis Berenbaum (Left) Luc Boblet, Revital Rattenbach, Jérôme Vailland (Right) This financing was secured from a pool of private investors and family offices, who chose to reinforce their commitment by investing directly at the subsidiary level in 4MB. The round includes a combination of equity and loans, reflecting a flexible capital structure aligned with long-term value creation. Thi
SBTS and ZIM Connections Bring Travel eSIM to Global Travelers10.2.2026 05:00:00 CET | Press release
New service leverages SoftBank Corp.’s wireless network in Japan SBTS, the joint venture between BTS and SoftBank Corp., and ZIM Connections today announced a strategic partnership to launch a travel eSIM solution, initially focused on inbound and outbound travel into and from Japan. The service is now live and commercially available here, marking the first step in a broader global rollout of multiple travel eSIM offerings. The initial launch is a digital travel eSIM platform developed by ZIM Connections and commercialized by SoftBank Corp. (“SoftBank”), a Japan-based telecommunications and IT operator. It enables travelers to easily search for, purchase, and activate unlimited global eSIM plans through a seamless digital experience. The first phase focuses on travelers visiting Japan as well as Japan-based travelers going abroad, leveraging SoftBank’s network for connectivity in the region. This launch represents a fully commercial market introduction, delivering immediate value to tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom